Generic drugs saved the nation’s health care system more than $824 billion from 2000 to 2009, according to an analysis by IMS Health, a health information company that tracks drug sales.
In 2009 alone, generic drugs saved the health system nearly $140 billion
View the Original article
Yet more restrictions in the use of anemia drugs are on the way.
Medicare issued final rules Monday that are expected to sharply curtail the use of anemia drugs, particularly Amgen’s Epogen, in the treatment of patients undergoing kidney dialysis.
However, after getting lots of protest, Medicare decided to exempt certain oral drugs from the new system until 2014, which could be good news for Genzyme.
Under the new system, the Centers for Medicare and Medicaid Services will pay a set fee for each dialysis treatment. That so-called bundled payment is supposed to cover both the dialysis service, in which wastes are removed from the body, and the drugs and laboratory tests that accompany it. The new system starts phasing in on Jan. 1.
The new system somewhat resembles concepts in the new health care law, but the dialysis system reform was initiated earlier by Congress, under different legislation.
Until now, Medicare has paid a set fee for the service but certain drugs, like Epogen, are reimbursed separately.
Critics say that gave hospitals and dialysis clinics financial incentives to use a lot of Epogen, which dominates the dialysis market because of Amgen’s patent position. Amgen sells about $2.5 billion of Epogen a year, virtually all for use in dialysis in the United States, and the drug is one of the biggest pharmaceutical expenses for Medicare.
Concern about this system grew stronger when some clinical trials revealed that overuse of Epogen might harm patients, increasing their risk of heart attacks and strokes.
View the Original article
I’ve been thinking a great deal about the newly formed Center for Medicare and Medicaid Innovation. (CMI). This entity was established as a result of the Affordable Care Act (the new healthcare reform legislation) and its purpose is to
View the Original article
After being a panelist at the Health 2.0 Goes to Washington Conference, Esther Dyson, Chairman of EDventure Holdings, gave a backstage interview. She talked about the three markets that influence Health 2.0; the market for healthcare, bad health, and health.
July 27, 2010
View the Original article
In final panel at Health 2.0 Goes to Washington the reactor panel, Will Yu (ONC), Esther Dyson (EDventure) and Chris Schroeder(Healthcentral) discussed health issues, and innovation in the healthcare system with Matthew Holt.
July 27, 2010SUBTEXT: At the start of the Health 2.0 Goes to Washington Conference, June 07, 2010, Matthew Holt and Indu Subaiya welcomed all of the conference attendees with an introduction to Health 2.0. In the middle of that introduction Wil Yu, Director of Innovation at the Office of the National Coordinator for Health IT (ONC), gave his opening remarks and spoke about health innovators and initiatives.
July 24, 2010The safety and quality movements have picked up tremendous steam over the past decade, but they haven’t yet hit that self-sustaining tipping point. Last week, there were two things that reminded me of this: the announcement of a new leader of the Institute for Healthcare Improvement (IHI), and a doleful JAMA essay by Peter Pronovost.
During the circus that was Don Berwick’s recess appointment to lead the Centers for Medicare & Medicaid Services (CMS), all eyes were trained Inside the Beltway. But 440 miles north, in Cambridge, MA, arguably the most important organization in the quality and safety galaxy needed to get on with its business. On July 8th, IHI announced its choice of Maureen Bisognano to become its new CEO. Maureen is a nurse and former hospital exec who has spent the last 15 years at IHI as Don’s consigliere. She is a terrific person, with boundless energy and great organizational skills
View the Original article
